Shares of ( CRM) gained $4.34, or 6.9%, to $67.01 after it raised full-year guidance and reported strong revenue growth in the first quarter. First-quarter revenue grew 52% to $247.6 million, and topped Street expectations of $235.8 million. Profit grew to $9.6 million, or 8 cents a share, from $730,000, or 1 cent a share, a year ago. Analysts were expecting EPS of 7 cents. For the full year, said it expects revenue to range from $1.06 billion to $1.065 billion, up from a previous projection of $1 billion to $1.02 billion and better than analysts' estimates of $1.045 billion in revenue.

Video-games retailer GameStop ( GME) lost $3.39, or 6.7%, to $47.45 after the company offered guidance that failed to impress investors. For the second quarter, GameStop said it expects EPS to range from 26 cents to 28 cents compared to earnings of 14 cents the year before. Analysts are looking for EPS of 26 cents. GameStop said full-year EPS could be range from $2.30 to $2.39. That compares to Street expectations of $2.33.

Meanwhile, shares of Houston-based ExpressJet Holdings ( XJT), which operates airline Continental Express, fell 42.5% to $1.57. The company said it would cut back on its schedule by 30%, citing higher fuel prices.

On the deal front, Myriad Genetics ( MYGN)shares rose after the company announced an agreement with Danish company Lundbeck A/S worth up to $350 million. Lundbeck, which markets the second most prescribed Alzheimer's drug in Europe, Ebixa (called Namenda in the U.S.), will pay Myriad $100 million upfront for outside-the-U.S. rights to Myriad's late-stage Alzheimer's drug Flurizan.

Myriad shares added $2.14, or 4.7%, to $48.21.

San Juan, Puerto Rico-based Santander Bancorp ( SBP) climbed 28.7% to $12.90. For the quarter ended March 31, the company reported income of $17.7 million, or 38 cents a share, vs. $11.7 million, or 25 cents a share, a year ago. Analysts surveyed by Thomson Reuters were expecting earnings of 13 cents a share.

Pfizer ( PFE) shares edged down 1.2% to $19.78, after a report from the Institute for Safe Medication Practices addressed disturbing side effects of its smoking-cessation drug Chantix and the subsequent decision by the FAA to ban the drug's use by pilots and air-traffic controllers.

According to the report, the drug is suspected in various adverse drug event reports, including serious accidents and falls, potentially lethal cardiac rhythm disturbances, seizures, psychosis, aggression and suicide, among other things. The Food and Drug Administration said in November that it was reviewing reports of erratic behavior and suicidal thoughts related to Chantix.
This article was written by a staff member of